RE: PYC23 Apr 2019 23:03
See thread below -
Market cap �2.5mln
72 million shares in issue
To buy 1% of PYC will only cost £25K (so cheap given the potential)
Cash �660k
Net cash used only �7k
Virtually profitable
Record revenues last 18mths
Share price 3.1p mid as of March 2019
[ ] Physiomics plc (AIM: PYC) is a solutions provider to the R&D-based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs
[ ] Results
Full yearResults came in at 90% increase and �512k ( see 8th Oct 2018 RNS) and loss after tax reduced by 54% with a small profit generated between Dec 2017 and June 2018
[ ] Cash and equivalents increased significantly to �552k at 31 December 2018, compared with �166k at 31 December 2017 and are relatively unchanged from £572k at 30 June 2018 (only �20k used from June 2018 to Dec 2018)
"total income for the period increased 162% to �372k compared with �142k in the comparable prior period "
Progess over the last 12mths
[ ] 5 major clients have signed clinical agreements, with 3 in just the 3mths from Nov 17- Feb 2018 .Including Nov deal with Merck whom PYC have worked with since 2012 and is for �500k and envisaged to be " a multi year agreement " with "one of the worlds top pharmaceutical companies". In Jan 2018 a new major company initially spending �35k and in Feb 2018 an initial �70k with a "major global top 10 client "
[ ] July 2018 Dr Claire Villette appointed to thw technical team.As a result of the significant volume of new business generated during the second half, the Company made the decision to hire a new full-time employee to supplement its delivery team. It was a testament to the raised profile of the Company that we were able to secure the services of a high-quality candidate
Presentations
[ ] Bio tech Showcase at JPMorgan week in San Francisco in January 2018 where they held 1-1 meetings with potential targeted clients
[ ] AACR American Association for Cancer Research April 2018. CEO Jim Millen and his team presented to over 21,000 clients and "touched base with current clients,all of whom were there, as well as meeetings with potential future clients
[ ] will attend key conferences, including the American Association for Cancer Research annual conference (29 March 2019 to 3 April 2019 in Atlanta, Georgia) where we will once again be presenting.
Jim Millen CEO - joined in 2016 with 15yrs experience across blue chip globals and smaller UK companies. Previously had a Business Development role at Glaxo
[ ] Merck deal renewed Dec 2018 for �490k for 2019
[ ] JP Morgan conference Jan 2019
[ ] In parallel with core commercial activities PYC are close to completing the most recent Innovate UK grant funded proje
Sign In
Follow the stocks
